| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Radiation Oncology, 2 Plastic Surgery, and 3 Pathology, Stanford University School of Medicine, Stanford; 4 FibroGen, Inc., South San Francisco, California; and 5 Department of Obstetrics and Gynecology, University of Leipzig, Leipzig, Germany
Requests for reprints: Amato Giaccia, Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Room 1255, CCSR South, 269 Campus Drive, Stanford, CA 94305. Phone: 650-723-7366; E-mail: giaccia{at}stanford.edu.
Pancreatic cancer is highly aggressive and refractory to most existing therapies. Past studies have shown that connective tissue growth factor (CTGF) expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer cell lines. To address whether and how CTGF influences tumor growth, we generated pancreatic tumor cell lines that overexpress different levels of human CTGF. The effect of CTGF overexpression on cell proliferation was measured in vitro in monolayer culture, suspension culture, or soft agar, and in vivo in tumor xenografts. Although there was no effect of CTGF expression on proliferation in two-dimensional cultures, anchorage-independent growth (AIG) was enhanced. The capacity of CTGF to enhance AIG in vitro was linked to enhanced pancreatic tumor growth in vivo when these cells were implanted s.c. in nude mice. Administration of a neutralizing CTGF-specific monoclonal antibody, FG-3019, had no effect on monolayer cell proliferation, but blocked AIG in soft agar. Consistent with this observation, anti-CTGF treatment of mice bearing established CTGF-expressing tumors abrogated CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity observed in normal tissue. Together, these studies implicate CTGF as a new target in pancreatic cancer and suggest that inhibition of CTGF with a human monoclonal antibody may control primary and metastatic tumor growth. (Cancer Res 2006; 66(11): 5816-27)
This article has been cited by other articles:
|
|
 |
|
  H. Zhang, C.-Y. Liu, Z.-Y. Zha, B. Zhao, J. Yao, S. Zhao, Y. Xiong, Q.-Y. Lei, and K.-L. Guan TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition J. Biol. Chem., May 15, 2009; 284(20): 13355 - 13362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-Y. Wang, P.-S. Chen, E. Prakash, H.-C. Hsu, H.-Y. Huang, M.-T. Lin, K.-J. Chang, and M.-L. Kuo Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1 Cancer Res., April 15, 2009; 69(8): 3482 - 3491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Crawford, M. A. Guney, Y. A. Oh, R. A. DeYoung, D. M. Valenzuela, A. J. Murphy, G. D. Yancopoulos, K. M. Lyons, D. R. Brigstock, A. Economides, et al. Connective Tissue Growth Factor (CTGF) Inactivation Leads to Defects in Islet Cell Lineage Allocation and {beta}-Cell Proliferation during Embryogenesis Mol. Endocrinol., March 1, 2009; 23(3): 324 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Bennewith, X. Huang, C. M. Ham, E. E. Graves, J. T. Erler, N. Kambham, J. Feazell, G. P. Yang, A. Koong, and A. J. Giaccia The Role of Tumor Cell-Derived Connective Tissue Growth Factor (CTGF/CCN2) in Pancreatic Tumor Growth Cancer Res., February 1, 2009; 69(3): 775 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zhao, X. Ye, J. Yu, L. Li, W. Li, S. Li, J. Yu, J. D. Lin, C.-Y. Wang, A. M. Chinnaiyan, et al. TEAD mediates YAP-dependent gene induction and growth control Genes & Dev., July 15, 2008; 22(14): 1962 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T C Mullis, X Tang, and K T Chong Expression of connective tissue growth factor (CTGF/CCN2) in head and neck squamous cell carcinoma J. Clin. Pathol., May 1, 2008; 61(5): 606 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Alvarez, A. Corvalan, J. C. Roa, P. Argani, F. Murillo, J. Edwards, R. Beaty, G. Feldmann, S.-M. Hong, M. Mullendore, et al. Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2631 - 2638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Z. Deng, P.-P. Chen, Y. Wang, D. Yin, H. P. Koeffler, B. Li, X.-J. Tong, and D. Xie Connective Tissue Growth Factor Is Overexpressed in Esophageal Squamous Cell Carcinoma and Promotes Tumorigenicity through -Catenin-T-cell Factor/Lef Signaling J. Biol. Chem., December 14, 2007; 282(50): 36571 - 36581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
CTGF in Pancreatic Cancer Cancer Res., August 1, 2006; 66(15): 7832 - 7832. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
